Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaSubgroupT-ALLICD10C91.0-C91.5-MeSHPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceT-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)ChemotherapyChemo-substanceNelarabinePeg asparaginaseChemo-substanceNelarabinePeg asparaginaseChemo-substanceNelarabinePeg asparaginaseChemo-substanceNelarabinePeg asparaginaseNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDimetindenFamotidineGranisetronParacetamolSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDimetindenFamotidineGranisetronParacetamolSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDimetindenFamotidineGranisetronParacetamolSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDimetindenFamotidineGranisetronParacetamolNo. Substances6Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseMaintenanceTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorRausch CRDiseaseHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieOriginDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasProtocols in Revision 1 protocol foundProtocols under revision.Nelarabine 650 / Peg-asparaginase 1500, T-ALL, maintenance, month 6, 7 (PID2083 V1.1)
